tHEORetically Speaking
Menu Close
  • Home
  • Guest Authors
  • About Us
  • HealthEconomics.Com
  • HE Jobs Portal

Author: Nicholas Emptage

0

Why We Still Don’t Know if Medicaid Affects Health Status

Posted on May 20, 2013 by Nicholas Emptage

If you’re reading this, chances are you’ve heard about the Oregon Medicaid study recently published in the New England Journal of Medicine.  In case you’ve been on vacation, however, the results were, at best, a disappointment to advocates of Medicaid: a… Continue Reading →

Guest Bloggers health policy, medicaid, Oregon, statistics
0

The Problem with Preventive Medicine

Posted on April 18, 2013 by Nicholas Emptage

The passage of the ACA in 2010 has to feel like a high-water mark for proponents of preventive medicine. The Obama health reform essentially makes free preventive care the law of the land, with insurers required to completely cover the… Continue Reading →

Guest Bloggers economics, Evidence-based medicine, health economics, health reform, prevention
0

When Analyzing Big Data Goes Wrong

Posted on March 26, 2013 by Nicholas Emptage

If you follow health policy these days, you may be finding yourself inundated with the hype over Big Data. Those of us with longer memories might caution that healthcare has leapt from fad to fad almost constantly over the past… Continue Reading →

Guest Bloggers big data, EHRs, healthcare, medical claims, social networking

About the HealthEconomics.Com Blog:

Insights, observations, executive interviews, critical analysis, and new research for health economics, outcomes research, real-world evidence, and market access community. We welcome guest bloggers.

Check your inbox or spam folder to confirm your subscription.

Recent Posts

  • How Accelerated Drug Development Requires Disruption in Market Access and Pricing
  • The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?
  • How to Change Clinical Practice Using Health Economics and Outcomes Research
  • Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?

HealthEconomics.Com Twitter Feed

HealthEconomics.Com | A Scientist.com Company Follow

www_healthecon
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
47m

ICER Review Casts Doubt on Value of Two ALS Drug Candidates

http://ow.ly/f0yP50KooR4

#HEOR #Pharma #DrugPricing #ValueAssessment #ICER

Reply on Twitter 1560768617796476928 Retweet on Twitter 1560768617796476928 Like on Twitter 1560768617796476928 Twitter 1560768617796476928
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
2h

New App from French Biotech Personalizes Drug Side Effects

http://ow.ly/IKPz50KooCP

#HEOR #Healthcare #Pharma #Therapeutics #DigitalHealth

Reply on Twitter 1560752797502607360 Retweet on Twitter 1560752797502607360 1 Like on Twitter 1560752797502607360 Twitter 1560752797502607360
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
3h

Cytel Webinar: US Drug Pricing Reform: Potential impact on Pharma HEOR Evidence Generation - September 8th

http://ow.ly/KAPc50KomRI

#HEOR #DrugPricing #Medicare #Pharma #ValueAssessment

Reply on Twitter 1560737131177410561 Retweet on Twitter 1560737131177410561 Like on Twitter 1560737131177410561 Twitter 1560737131177410561
Load More...

Archives

Visit our website, HealthEconomics.Com, top ranked by Google for news, jobs and resources in healthcare value, market access and more. Read our privacy policy here.
© 2022 tHEORetically Speaking. All rights reserved.
Hiero by aThemes